T cell mixed chimerism is significantly correlated to a decreased risk of acute graft-versus-host disease after allogeneic stem cell transplantation

被引:76
作者
Mattsson, J
Uzunel, M
Remberger, M
Ringdén, O
机构
[1] Karolinska Inst, Ctr Allogeneic Stem Cell Transplantat, Huddinge Hosp, SE-14186 Huddinge, Sweden
[2] Karolinska Inst, Dept Clin Immunol, Huddinge Hosp, SE-14186 Huddinge, Sweden
关键词
D O I
10.1097/00007890-200102150-00017
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background It has been debated whether mixed chimerism (MC) is correlated to a decreased incidence of graft-versus-host disease (GVHD) after allogeneic stem cell transplantation (SCT). Methods. Between September 1996 and April 1999 we analyzed 102 patients for MC in the T-cell fraction post allogeneic SCT, using PCR amplification of variable numbers of tandem repeat (VNTR) loci. All samples, taken regularly post SCT, were cell separated using anti-CDS immunomagnetic beads. Results. T-cell mixed chimerism was detected in 58 out of 102 patients (57%), Patient characteristics were comparable in the T-cell MC- and donor chimeric-group (DC), The median follow-up time for the MC group was 714 days (range 58 - 1248) as compared to 427 days (range 45 - 1042) for the DC group. Overall probability of acute GVHD grades II-IV was significantly higher in the DC group as compared to the MC group (52% vs. 5%, P<0.001). In multivariate analysis T-cell DC proved to be the most significant risk factor for acute GVHD grades II-IV. The cumulative incidence of relapse, among patients with malignant disease, did not show any statistical difference between the T-cell MC patients and the DC-group, There was a tendency for better overall survival in the T-cell MC group compared to the DC group (2 yrs; 73% vs. 54%, P=0.06), Among DC patients, 14/20 (70%) deaths were due to GVHD versus none in the MC-group(P<0.001). Conclusion. T-cell mixed chimerism was significantly correlated to a decreased risk of moderate to severe acute GVHD and death by GVHD.
引用
收藏
页码:433 / 439
页数:7
相关论文
共 41 条
[11]  
HOROWITZ MM, 1990, BLOOD, V75, P555
[12]  
Huss R, 1996, BONE MARROW TRANSPL, V18, P767
[13]  
ILDSTAD ST, 1986, J IMMUNOL, V136, P28
[14]  
Kalbfleisch J.D., 1980, The statistical analysis of failure time data
[15]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481
[16]  
KEEVER CA, 1989, BLOOD, V73, P1340
[17]   DONOR LEUKOCYTE TRANSFUSIONS FOR TREATMENT OF RECURRENT CHRONIC MYELOGENOUS LEUKEMIA IN MARROW TRANSPLANT PATIENTS [J].
KOLB, HJ ;
MITTERMULLER, J ;
CLEMM, C ;
HOLLER, E ;
LEDDEROSE, G ;
BREHM, G ;
HEIM, M ;
WILMANNS, W .
BLOOD, 1990, 76 (12) :2462-2465
[18]   Graft-versus-host disease and the Th1/Th2 paradigm [J].
Krenger, W ;
Ferrara, JLM .
IMMUNOLOGIC RESEARCH, 1996, 15 (01) :50-73
[19]   THE FUNCTIONAL AND HISTOLOGICAL BASIS FOR GRAFT-VERSUS-HOST-INDUCED IMMUNOSUPPRESSION [J].
LAPP, WS ;
GHAYUR, T ;
MENDES, M ;
SEDDIK, M ;
SEEMAYER, TA .
IMMUNOLOGICAL REVIEWS, 1985, 88 :107-133
[20]  
MACKINNON S, 1994, BLOOD, V83, P3409